Dan Atar

• Sandberg, Edvard Liljedahl; Halvorsen, Sigrun; Berge, Trygve; Grimsmo, Jostein; Atar, Dan & Grenne, Bjørnar Leangen [Show all 7 contributors for this article] (2024). Screening for Atrial Fibrillation by Digital Health Technology in Older People in Homecare Settings: A Feasibility Trial. International Journal of Telemedicine and Applications. ISSN 1687-6415. 2024. doi: 10.1155/2024/4080415.
• Landi, Antonio; Aboyans, Victor; Angiolillo, Dominick J.; Atar, Dan; Capodanno, Davide & Fox, Keith A.A. [Show all 22 contributors for this article] (2024). Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines. European Heart Journal: Acute Cardiovascular Care. ISSN 2048-8726. 13(1), p. 173–180. doi: 10.1093/ehjacc/zuad158.
• McClintick, Daniel J.; O'Donoghue, Michelle L.; De Ferrari, Gaetano M.; Ferreira, Jorge; Ran, Xinhui & Im, KyungAh [Show all 14 contributors for this article] (2024). Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease. Journal of the American College of Cardiology. ISSN 0735-1097. 83(6), p. 652–664. doi: 10.1016/j.jacc.2023.11.029.
• Nordlund, David; Lav, Theodor; Jablonowski, Robert; Khoshnood, Ardavan; Ekelund, Ulf & Atar, Dan [Show all 9 contributors for this article] (2024). Contractility, ventriculoarterial coupling, and stroke work after acute myocardial infarction using CMR-derived pressure-volume loop data. Clinical Cardiology. ISSN 0160-9289. 47(1). doi: 10.1002/clc.24216.
• Healey, Jeff S.; Lopes, Renato D.; Granger, Christopher B.; Alings, Marco; Rivard, Lena & McIntyre, William F. [Show all 37 contributors for this article] (2023). Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. New England Journal of Medicine. ISSN 0028-4793. 390(2), p. 107–117. doi: 10.1056/NEJMoa2310234. Full text in Research Archive
• Lundin, Magnus; Heiberg, Einar; Nordlund, David; Gyllenhammar, Tom; Steding-Ehrenborg, Katarina & Engblom, Henrik [Show all 26 contributors for this article] (2023). Prognostic utility and characterization of left ventricular hypertrophy using global thickness. Scientific Reports. ISSN 2045-2322. 13(1). doi: 10.1038/s41598-023-48173-7. Full text in Research Archive
• Pope, Marita Knudsen; Hall, Trygve Sørdahl; Virdone, Saverio; Atar, Dan; John Camm, Camm & Pieper, Karen S [Show all 13 contributors for this article] (2023). Rhythm versus rate control in patients with newly diagnosed atrial fibrillation – Observations from the GARFIELD-AF registry. International journal of cardiology: Heart and Vasculature (IJCHA). ISSN 2352-9067. 49. doi: 10.1016/j.ijcha.2023.101302. Full text in Research Archive
• Kristensen, Anna Meta Dyrvig; Munkhaugen, John; Halvorsen, Sigrun; Olsen, Michael Hecht; Bakken, Arnhild & Sehested, Thomas Steen Gyldenstierne [Show all 12 contributors for this article] (2023). The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics . European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. doi: 10.1093/ehjcvp/pvad093.
• Serebruany, Victor L.; Tanguay, Jean-Francois; Gurvich, Milana L.; Marciniak, Thomas A. & Atar, Dan (2023). Strokes and Transient Ischemic Attacks Occurrence during Annual Dual Antiplatelet Therapy. American Journal of Therapeutics. ISSN 1075-2765. 30(5), p. E411–E415. doi: 10.1097/MJT.0000000000001622.
• Atar, Dan; Auricchio, Angelo & Blomström-Lundqvist, Carina (2023). Cardiac device infection: removing barriers to timely and adequate treatment. European Heart Journal. ISSN 0195-668X. 44(35), p. 3323–3326. doi: 10.1093/eurheartj/ehad490. Full text in Research Archive
• Fröhlich, Hanna; Bossmeyer, Anna; Kazmi, Syed; Goode, Kevin M.; Agewall, Stefan & Atar, Dan [Show all 12 contributors for this article] (2023). Glycaemic control and insulin therapy are significant confounders of the obesity paradox in patients with heart failure and diabetes mellitus. Clinical Research in Cardiology. ISSN 1861-0684. doi: 10.1007/s00392-023-02268-3. Full text in Research Archive Show summary

  Background: A high body mass index (BMI) confers a paradoxical survival benefit in patients with heart failure (HF) or diabetes mellitus (DM). There is, however, controversy whether an obesity paradox is also present in patients with HF and concomitant DM. In addition, the influence of glycaemic control and diabetes treatment on the presence or absence of the obesity paradox in patients with HF and DM is unknown. Methods: We identified 2936 patients with HF with reduced ejection fraction (HFrEF) in the HF registries of the universities of Heidelberg, Germany, and Hull, UK (general sample). Of these, 598 (20%) were treated for concomitant DM (DM subgroup). The relationship between BMI and all-cause mortality was analysed in both the general sample and the DM subgroup. Patients with concomitant DM were stratified according to HbA1c levels or type of diabetes treatment and analyses were repeated. Results: We found an inverse BMI-mortality relationship in both the general sample and the DM subgroup. However, the obesity paradox was less pronounced in patients with diabetes treated with insulin and it disappeared in those with poor glycaemic control as defined by HbA1c levels > 7.5%. Conclusion: In patients with HFrEF, a higher BMI is associated with better survival irrespective of concomitant DM. However, insulin treatment and poor glycaemic control make the relationship much weaker. Keywords: Diabetes mellitus; Heart failure; Mortality; Obesity paradox; Reverse epidemiology. © 2023. The Author(s).

• Jervan, Øyvind; Haukeland-Parker, Stacey Marie; Gleditsch, Jostein; Tavoly, Mazdak; Klok, Frederikus A. & Steine, Kjetil [Show all 14 contributors for this article] (2023). The Effects of Exercise Training in Patients With Persistent Dyspnea Following Pulmonary Embolism: A Randomized Controlled Trial. Chest. ISSN 0012-3692. 164(4), p. 981–991. doi: 10.1016/j.chest.2023.04.042. Full text in Research Archive
• Valgimigli, Marco; Aboyans, Victor; Angiolillo, Dominick; Atar, Dan; Capodanno, Davide & Halvorsen, Sigrun [Show all 23 contributors for this article] (2023). Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 9(5), p. 462–496. doi: 10.1093/ehjcvp/pvad032.
• Sandberg, Edvard Liljedahl; Halvorsen, Sigrun; Berge, Trygve; Grimsmo, Jostein; Atar, Dan & Fensli, Rune Werner [Show all 8 contributors for this article] (2023). Fully digital self-screening for atrial fibrillation with patch electrocardiogram. Europace. ISSN 1099-5129. 25(5). doi: 10.1093/europace/euad075. Full text in Research Archive Show summary

  Aims Atrial fibrillation (AF) is the most common arrhythmia worldwide. The AF is associated with severe mortality, morbidity, and healthcare costs, and guidelines recommend screening people at risk. However, screening methods and organization still need to be clarified. The current study aimed to assess the feasibility of a fully digital self-screening procedure and to assess the prevalence of undetected AF using a continuous patch electrocardiogram (ECG) monitoring system. Methods and results Individuals ≥65 years old with at least one additional risk factor for stroke from the general population of Norway were invited to a fully digital continuous self-screening for AF using a patch ECG device (ECG247 Smart Heart Sensor). Participants self-reported clinical characteristics and usability online, and all participants received digital feedback of their results. A total of 2118 individuals with a mean CHA2DS2-VASc risk score of 2.6 (0.9) were enrolled in the study [74% women; mean age 70.1 years (4.2)]. Of these, 1849 (87.3%) participants completed the ECG self-screening test, while 215 (10.2%) did not try to start the test and 54 (2.5%) failed to start the test. The system usability score was 84.5. The mean ECG monitoring time was 153 h (87). Atrial fibrillation was detected in 41 (2.2%) individuals. Conclusion This fully digitalized self-screening procedure for AF demonstrated excellent feasibility. The number needed to screen was 45 to detect one unrecognized case of AF in subjects at risk for stroke. Randomized studies with long-term follow-up are needed to assess whether self-screening for AF can reduce the incidence of AF-related complications

• Navarese, Eliano Pio; Landi, Antonio; Oliva, Angelo; Piccolo, Raffaele; Aboyans, Victor & Angiolillo, Dominick [Show all 23 contributors for this article] (2023). Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC). European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 9(3), p. 271–290. doi: 10.1093/ehjcvp/pvad016.
• Gaba, Prakriti; O'Donoghue, Michelle L.; Park, Jeong-Gun; Wiviott, Stephen D.; Atar, Dan & Kuder, Julia F. [Show all 23 contributors for this article] (2023). Association between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. ISSN 0009-7322. 147(16), p. 1192–1203. doi: 10.1161/CIRCULATIONAHA.122.063399.
• Ratajczak-Tretel, Barbara; Lambert, Anna Tancin; Al-Ani, Riadh Ibrahim Mahmud; Arntzen, Kathrine Grønning; Bakkejord, Grete & Bekkeseth, Hanna Marie Otterholt [Show all 32 contributors for this article] (2023). Prediction of underlying atrial fibrillation in patients with a cryptogenic stroke: results from the NOR-FIB Study. Journal of Neurology. ISSN 0340-5354. 270, p. 4049–4059. doi: 10.1007/s00415-023-11680-8. Full text in Research Archive Show summary

  Background Atrial fibrillation (AF) detection and treatment are key elements to reduce recurrence risk in cryptogenic stroke (CS) with underlying arrhythmia. The purpose of the present study was to assess the predictors of AF in CS and the utility of existing AF-predicting scores in The Nordic Atrial Fibrillation and Stroke (NOR-FIB) Study. Method The NOR-FIB study was an international prospective observational multicenter study designed to detect and quantify AF in CS and cryptogenic transient ischaemic attack (TIA) patients monitored by the insertable cardiac monitor (ICM), and to identify AF-predicting biomarkers. The utility of the following AF-predicting scores was tested: AS5F, Brown ESUS-AF, CHA2DS2-VASc, CHASE-LESS, HATCH, HAVOC, STAF and SURF. Results In univariate analyses increasing age, hypertension, left ventricle hypertrophy, dyslipidaemia, antiarrhythmic drugs usage, valvular heart disease, and neuroimaging findings of stroke due to intracranial vessel occlusions and previous ischemic lesions were associated with a higher likelihood of detected AF. In multivariate analysis, age was the only independent predictor of AF. All the AF-predicting scores showed significantly higher score levels for AF than non-AF patients. The STAF and the SURF scores provided the highest sensitivity and negative predictive values, while the AS5F and SURF reached an area under the receiver operating curve (AUC) > 0.7. Conclusion Clinical risk scores may guide a personalized evaluation approach in CS patients. Increasing awareness of the usage of available AF-predicting scores may optimize the arrhythmia detection pathway in stroke units.

• Bondjers, Kristina; Lingaas, Ingebjørg; Stensland, Synne; Atar, Dan; Zwart, John Anker Henrik & Wøien, Hilde [Show all 7 contributors for this article] (2023). “I’ve kept going” – a multisite repeated cross-sectional study of healthcare workers’ pride in personal performance during the COVID-19 pandemic. BMC Health Services Research. ISSN 1472-6963. 23(1). doi: 10.1186/s12913-023-09246-5. Full text in Research Archive
• Serebruany, Victor L.; Tanguay, Jean-Francois; Gurvich, Milana L.; Marciniak, Thomas A. & Atar, Dan (2023). Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year. American Journal of Medicine. ISSN 0002-9343. doi: 10.1016/j.amjmed.2023.01.029.
• Ratajczak-Tretel, Barbara; Lambert, Anna Tancin; Al-Ani, Riadh Ibrahim Mahmud; Bekkeseth, Hanna Marie Otterholt; Bakkejord, Grete & Bjerkeli, Vigdis [Show all 31 contributors for this article] (2023). Underlying causes of cryptogenic stroke and TIA in the nordic atrial fibrillation and stroke (NOR-FIB) study – the importance of comprehensive clinical evaluation. BMC Neurology. ISSN 1471-2377. 23(1), p. 1–10. doi: 10.1186/s12883-023-03155-0. Full text in Research Archive Show summary

  Background Cryptogenic stroke is a heterogeneous condition, with a wide spectrum of possible underlying causes for which the optimal secondary prevention may differ substantially. Attempting a correct etiological diagnosis to reduce the stroke recurrence should be the fundamental goal of modern stroke management. Methods Prospective observational international multicenter study of cryptogenic stroke and cryptogenic transient ischemic attack (TIA) patients clinically monitored for 12 months to assign the underlying etiology. For atrial fibrillation (AF) detection continuous cardiac rhythm monitoring with insertable cardiac monitor (Reveal LINQ, Medtronic) was performed. The 12-month follow-up data for 250 of 259 initially included NOR-FIB patients were available for analysis. Results After 12 months follow-up probable stroke causes were revealed in 43% patients, while 57% still remained cryptogenic. AF and atrial flutter was most prevalent (29%). In 14% patients other possible causes were revealed (small vessel disease, large-artery atherosclerosis, hypercoagulable states, other cardioembolism). Patients remaining cryptogenic were younger (p<0.001), had lower CHA2DS2-VASc score (p<0.001) on admission, and lower NIHSS score (p=0.031) and mRS (p=0.016) at discharge. Smoking was more prevalent in patients that were still cryptogenic (p=0.014), while dyslipidaemia was less prevalent (p=0.044). Stroke recurrence rate was higher in the cryptogenic group compared to the group where the etiology was revealed, 7.7% vs. 2.8%, (p=0.091). Conclusion Cryptogenic stroke often indicates the inability to identify the cause in the acute phase and should be considered as a working diagnosis until efforts of diagnostic work up succeed in identifying a specific underlying etiology. Timeframe of 6-12-month follow-up may be considered as optimal. Trial registration ClinicalTrials.gov Identifier NCT02937077, EudraCT 2018-002298-23

• Lambert, Anna Tancin; Ratajczak-Tretel, Barbara; Al-Ani, Riadh Ibrahim Mahmud; Arntzen, Kathrine Grønning; Bakkejord, Grete & Bekkeseth, Hanna Marie Otterholt [Show all 35 contributors for this article] (2023). Biomarkers predictive of atrial fibrillation in patients with cryptogenic stroke. Insights from the Nordic Atrial Fibrillation and Stroke (NOR-FIB) study. European Journal of Neurology. ISSN 1351-5101. 30(5), p. 1352–1363. doi: 10.1111/ene.15746. Show summary

  Background There are currently no biomarkers used to select cryptogenic stroke (CS) patients for monitoring with insertable cardiac monitors (ICMs), the most effective tool for diagnosing atrial fibrillation (AF) in CS. The purpose of this study was to assess clinically available biomarkers as predictors of AF. Methods Eligible CS and cryptogenic transient ischemic attack (TIA) patients underwent 12-month monitoring with ICMs, clinical follow-up, and biomarker sampling. Levels of cardiac and thromboembolic biomarkers, taken within 14 days from symptom onset, were compared between patients diagnosed with AF (n=74) during monitoring and those without AF (n=185). Receiver operating characteristic (ROC) curves were created. Biomarkers reaching area under ROC curve (AUC) ≥ 0.7 were dichotomized by finding optimal cut-off values and used in logistic regression establishing their predictive value for increased risk of AF in unadjusted and adjusted models. Results B-type natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase, D-dimer, high-sensitivity cardiac Troponin I and T were significantly higher in the AF than non-AF group. BNP and NT-proBNP reached predefined AUC level, 0.755 and 0.725 respectively. Optimal cut-off values were 33.5 ng/L for BNP, and 87 ng/L for NT-proBNP. Regression analysis showed that NT-proBNP was a predictor of AF in both unadjusted, odds ratio (OR) 7.72 (95% confidence interval [CI] 3.16–18.87), and age and sex adjusted models, OR 4.82 (95% CI 1.79–12.96). Conclusion Several clinically established biomarkers were associated with AF. NT-proBNP performed best as AF predictor and could be used for selecting patients for long-term monitoring with ICMs.

• Atar, Dan; Rosseland, Leiv Arne; Jammer, Ib; Aakre, Kristin Moberg; Wiseth, Rune & Molund, Marius [Show all 8 contributors for this article] (2022). Implementing screening for myocardial injury in non-cardiac surgery: perspectives of an ad-hoc interdisciplinary expert group. Scandinavian Cardiovascular Journal. ISSN 1401-7431. 57(1), p. 31–39. doi: 10.1080/14017431.2022.2112071. Full text in Research Archive Show summary

  Objectives. Perioperative myocardial injury (PMI) is increasingly recognised as an important complication of non-cardiac surgery, with often clinically silent presentation, but detrimental prognosis. Active screening for PMI, involving the detection of dynamic and elevated levels of cardiac troponin, has recently been advocated by an increasing number of guidelines; however, active PMI screening has not been reflected in clinical practice. Design. As consensus on a common screening and management pathway is lacking, we synthesise the current evidence to provide suggestions on the selection of patients for screening, organisation of a screening program, and a potential management pathway, building upon a recently published perioperative screening algorithm. Results. Screening should be performed using high-sensitivity assays both preoperatively and postoperatively (postoperative Days 1 and 2) in patients at high-risk of experiencing perioperative complications. Conclusion. This expert opinion piece by an interdisciplinary group of predominantly Norwegian clinicians aims to assist healthcare professionals planning to implement guideline-recommended PMI screening at a local level in order to improve patient outcomes following non-cardiac surgery.

• Ratajczak-Tretel, Barbara; Lambert, Anna Tancin; Atar, Dan & Aamodt, Anne Hege (2022). Cryptogenic stroke and TIA: Suggested diagnostic approach while waiting for evaluation and treatment guidelines. Acta Neurologica Scandinavica. ISSN 0001-6314. 145(5), p. 641–646. doi: 10.1111/ane.13590. Full text in Research Archive
• Halvorsen, Sigrun; Mehilli, Julinda; Cassese, Salvatore; Hall, Trygve Sørdahl; Schirmer, Henrik & Atar, Dan [Show all 7 contributors for this article] (2022). 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European Heart Journal. ISSN 0195-668X. doi: 10.1093/eurheartj/ehac270.
• Heiberg, Einar; Engblom, Henrik; Carlsson, Marcus; Erlinge, David; Atar, Dan & Aletras, Anthony H. [Show all 7 contributors for this article] (2022). Infarct quantification with cardiovascular magnetic resonance using "standard deviation from remote" is unreliable: validation in multi-centre multi-vendor data. Journal of Cardiovascular Magnetic Resonance. ISSN 1097-6647. 24(1). doi: 10.1186/s12968-022-00888-8. Full text in Research Archive
• Atar, Dan; Sarkar, Sougat; Kolev, Emil; Mura, Carla; Brosstad, Frank Roger & Theodorsen, Lotte [Show all 8 contributors for this article] (2022). Randomized, open-label, crossover trial comparing the pharmacokinetic profile of a novel oral aspirin solution and a chewed aspirin tablet. International Journal of Clinical Pharmacology and Therapeutics. ISSN 0946-1965. 60(10), p. 430–438. doi: 10.5414/CP204271.
• Kotecha, Dipak; Asselbergs, Folkert W.; Achenbach, Stephan; Anker, Stefan D.; Atar, Dan & Baigent, Colin [Show all 44 contributors for this article] (2022). CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research. European Heart Journal. ISSN 0195-668X. 43(37), p. 3578–3588. doi: 10.1093/eurheartj/ehac426. Full text in Research Archive
• O'Donoghue, Michelle L.; Giugliano, Robert P.; Wiviott, Stephen D.; Atar, Dan; Keech, Anthony & Kuder, Julia F. [Show all 15 contributors for this article] (2022). Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation. ISSN 0009-7322. 146(15), p. 1109–1119. doi: 10.1161/CIRCULATIONAHA.122.061620.
• Kotecha, Dipak; Asselbergs, Folkert W; Achenbach, Stephan; Anker, Stefan D; Atar, Dan & Baigent, Colin [Show all 44 contributors for this article] (2022). CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research. The Lancet Digital Health. ISSN 2589-7500. 4(10), p. e757–e764. doi: 10.1016/S2589-7500(22)00151-0. Full text in Research Archive
• Atar, Dan; Langslet, Gisle & Tonstad, Serena (2022). Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances. Kardiologia polska. ISSN 0022-9032. 80(7-8), p. 741–749. doi: 10.33963/KP.a2022.0117. Full text in Research Archive
• Butt, Jawad H.; Dewan, Pooja; Jhund, Pardeep S.; Anand, Inder S.; Atar, Dan & Ge, Junbo [Show all 24 contributors for this article] (2022). Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. ISSN 0735-1097. 80(12), p. 1130–1143. doi: 10.1016/j.jacc.2022.06.037. Full text in Research Archive
• Triska, Jeffrey; Maitra, Neil; Deshotels, Matthew R.; Haddadin, Faris; Angiolillo, Dominick J. & Vilahur, Gemma [Show all 9 contributors for this article] (2022). A Comprehensive Review of the Pleiotropic Effects of Ticagrelor. Cardiovascular Drugs and Therapy. ISSN 0920-3206. doi: 10.1007/s10557-022-07373-5. Full text in Research Archive
• Vitolo, Marco; Proietti, Marco; Malavasi, Vincenzo L.; Bonini, Niccolo’; Romiti, Giulio Francesco & Imberti, Jacopo F. [Show all 49 contributors for this article] (2022). Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry. European journal of internal medicine. ISSN 0953-6205. 105, p. 54–62. doi: 10.1016/j.ejim.2022.08.004.
• Ratajczak-Tretel, Barbara; Lambert, Anna Tancin; Al-Ani, Riadh Ibrahim Mahmud; Arntzen, Kathrine Grønning; Bakkejord, Grete & Bekkeseth, Hanna Marie Otterholt [Show all 33 contributors for this article] (2022). Atrial fibrillation in cryptogenic stroke and TIA patients in The Nordic Atrial Fibrillation and Stroke (NOR-FIB) Study: Main results. European Stroke Journal. ISSN 2396-9873. 8(1), p. 148–156. doi: 10.1177/23969873221123122. Full text in Research Archive Show summary

  Introduction: Secondary stroke prevention depends on proper identification of the underlying etiology and initiation of optimal treatment after the index event. The aim of the NOR-FIB study was to detect and quantify underlying atrial fibrillation (AF) in patients with cryptogenic stroke (CS) or transient ischaemic attack (TIA) using insertable cardiac monitor (ICM), to optimise secondary prevention, and to test the feasibility of ICM usage for stroke physicians. Patients and methods: Prospective observational international multicenter real-life study of CS and TIA patients monitored for 12 months with ICM (Reveal LINQ) for AF detection. Results: ICM insertion was performed in 91.5% by stroke physicians, within median 9 days after index event. Paroxysmal AF was diagnosed in 74 out of 259 patients (28.6%), detected early after ICM insertion (mean 48 ± 52 days) in 86.5% of patients. AF patients were older (72.6 vs 62.2; p< 0.001), had higher pre-stroke CHA₂DS₂-VASc score (median 3 vs 2; p< 0.001) and admission NIHSS (median 2 vs 1; p= 0.001); and more often hypertension (p = 0.045) and dyslipidaemia (p = 0.005) than non-AF patients. The arrhythmia was recurrent in 91.9% and asymptomatic in 93.2%. At 12-month follow-up anticoagulants usage was 97.3%.Discussion and conclusions: ICM was an effective tool for diagnosing underlying AF, capturing AF in 29% of the CS and TIA patients. AF was asymptomatic in most cases and would mainly have gone undiagnosed without ICM. The insertion and use of ICM was feasible for stroke physicians in stroke units. © The Author(s) 2022.

• Johannessen, Tonje Rambøll; Halvorsen, Sigrun; Atar, Dan; Munkhaugen, John; Nore, Anne Kathrine & Wisløff, Torbjørn [Show all 7 contributors for this article] (2022). Cost-effectiveness of a rule-out algorithm of acute myocardial infarction in low-risk patients: emergency primary care versus hospital setting. BMC Health Services Research. ISSN 1472-6963. 22(1). doi: 10.1186/s12913-022-08697-6. Full text in Research Archive Show summary

  Aims: Hospital admissions of patients with chest pain considered as low risk for acute coronary syndrome contribute to increased costs and crowding in the emergency departments. This study aims to estimate the cost-effectiveness of assessing these patients in a primary care emergency setting, using the European Society of Cardiology (ESC) 0/1-h algorithm for high-sensitivity cardiac troponin T, compared to routine hospital management. Methods: A cost-effectiveness analysis was conducted. For the primary care estimates, costs and health care expenditure from the observational OUT-ACS (One-hoUr Troponin in a low-prevalence population of Acute Coronary Syndrome) study were compared with anonymous extracted administrative data on low-risk patients at a large general hospital in Norway. Patients discharged home after the hs-cTnT assessment were defined as low risk in the primary care cohort. In the hospital setting, the low-risk group comprised patients discharged with a non-specific chest pain diagnosis (ICD-10 codes R07.4 and Z03.5). Loss of health related to a potential increase in acute myocardial infarctions the following 30-days was estimated. The primary outcome measure was the costs per quality-adjusted life year (QALY) of applying the ESC 0/1-h algorithm in primary care. The secondary outcomes were health care costs and length of stay in the two settings. Results: Differences in costs comprise personnel and laboratory costs of applying the algorithm at primary care level (€192) and expenses related to ambulance transports and complete hospital costs for low-risk patients admitted to hospital (€1986). Additional diagnostic procedures were performed in 31.9% (181/567) of the low-risk hospital cohort. The estimated reduction in health care cost when using the 0/1-h algorithm outside of hospital was €1794 per low-risk patient, with a mean decrease in length of stay of 18.9 h. These numbers result in an average per-person QALY gain of 0.0005. Increased QALY and decreased costs indicate that the primary care approach is clearly cost-effective. Conclusion: Using the ESC 0/1-h algorithm in low-risk patients in emergency primary care appears to be cost-effective compared to standard hospital management, with an extensive reduction in costs and length of stay per patient.

• Saldarriaga, Clara; Atar, Dan; Stebbins, Amanda; Lewis, Basil S.; Abidin, Imran Zainal & Blaustein, Robert O. [Show all 17 contributors for this article] (2022). Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. European Journal of Heart Failure. ISSN 1388-9842. 24(5), p. 782–790. doi: 10.1002/ejhf.2468.
• Kotecha, Dipak; Asselbergs, Folkert W; Achenbach, Stephan; Anker, Stefan D; Atar, Dan & Baigent, Colin [Show all 44 contributors for this article] (2022). CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research. The BMJ. ISSN 1756-1833. p. 1–9. doi: 10.1136/bmj-2021-069048. Full text in Research Archive
• Fyksen, Tea Sætereng; Vanberg, Paul; Gjesdal, Knut Tjøl; von Lueder, Thomas Gero; Bjørnerheim, Reidar & Steine, Kjetil [Show all 8 contributors for this article] (2022). Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes. Scandinavian Journal of Medicine & Science in Sports. ISSN 0905-7188. 32(8), p. 1170–1181. doi: 10.1111/sms.14172. Full text in Research Archive
• Serebruany, Victor L.; Tanguay, Jean-François; Kuliczkowski, Wiktor; Heidel, Eric; Kim, Moo Hyun & Atar, Dan (2022). Impact of Bleeding on Myocardial Infarction, Stroke, and Death During 12 Months Dual Antiplatelet Therapy After Acute Coronary Syndrome. American Journal of Medicine. ISSN 0002-9343. doi: 10.1016/j.amjmed.2022.07.022.
• Korthauer, Laura E.; Giugliano, Robert P.; Guo, Jianping; Sabatine, Marc S.; Sever, Peter & Keech, Anthony [Show all 11 contributors for this article] (2022). No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PLOS ONE. ISSN 1932-6203. 17(4). doi: 10.1371/journal.pone.0266615. Full text in Research Archive
• Moschetti, Karine; Kwong, Raymond Y.; Petersen, Steffen E.; Lombardi, Massimo; Garot, Jerome & Atar, Dan [Show all 19 contributors for this article] (2022). Cost-Minimization Analysis for Cardiac Revascularization in 12 Health Care Systems Based on the EuroCMR/SPINS Registries. JACC Cardiovascular Imaging. ISSN 1936-878X. 15(4), p. 607–625. doi: 10.1016/j.jcmg.2021.11.008. Full text in Research Archive
• Ye, Regina; Jneid, Hani; Alam, Mahboob; Uretsky, Barry F.; Atar, Dan & Kitakaze, Masafumi [Show all 9 contributors for this article] (2022). Do We Really Need Aspirin Loading for STEMI? Cardiovascular Drugs and Therapy. ISSN 0920-3206. doi: 10.1007/s10557-022-07327-x. Full text in Research Archive
• Birnbaum, Yochai; Rankinen, Jani; Jneid, Hani; Atar, Dan & Nikus, Kjell (2022). The Role of ECG in the Diagnosis and Risk Stratification of Acute Coronary Syndromes: an Old but Indispensable Tool. Current Cardiology Reports. ISSN 1523-3782. 24(2), p. 109–118. doi: 10.1007/s11886-021-01628-7. Full text in Research Archive
• Thind, Munveer; Zareba, Wojciech; Atar, Dan; Crijns, Harry J. G. M.; Zhu, Jun & Pak, Hui-Nam [Show all 11 contributors for this article] (2022). Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials. Clinical Cardiology. ISSN 0160-9289. 45(1), p. 101–109. doi: 10.1002/clc.23765. Full text in Research Archive
• Johannessen, Tonje Rambøll; Halvorsen, Sigrun; Atar, Dan & Vallersnes, Odd Martin (2022). Performance of the Novel Observation Group Criteria of the European Society of Cardiology (ESC) 0/1-Hour Algorithm in a Low-Risk Population. Journal of the American Heart Association (JAHA). ISSN 2047-9980. 11(7). doi: 10.1161/JAHA.121.024927. Full text in Research Archive
• Hall, Trygve Sørdahl; Ørn, Stein; Zannad, Faiez; Rossignol, Patrick; Duarte, Kevin & Solomon, Scott D. [Show all 10 contributors for this article] (2022). The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. Journal of Women's Health. ISSN 1540-9996. 31(3), p. 310–320. doi: 10.1089/jwh.2021.0326.
• Steffel, Jan; Collins, Ronan; Antz, Matthias; Cornu, Pieter; Desteghe, Lien & Haeusler, Karl Georg [Show all 28 contributors for this article] (2021). 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. ISSN 1099-5129. 23(10), p. 1612–1676. doi: 10.1093/europace/euab065.
• Gonzales, Ricardo A.; Seemann, Felicia; Lamy, Jérôme; Mojibian, Hamid; Atar, Dan & Erlinge, David [Show all 12 contributors for this article] (2021). MVnet: automated time-resolved tracking of the mitral valve plane in CMR long-axis cine images with residual neural networks: a multi-center, multi-vendor study. Journal of Cardiovascular Magnetic Resonance. ISSN 1097-6647. 23(1), p. 1–15. doi: 10.1186/s12968-021-00824-2. Full text in Research Archive
• Allahham, Mahmoud; Lerman, A.; Atar, Dan & Birnbaum, Yochai (2021). Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era. Cardiovascular Drugs and Therapy. ISSN 0920-3206. doi: 10.1007/s10557-021-07224-9. Full text in Research Archive
• Sandberg, Edvard Liljedahl; Grenne, Bjørnar; Berge, Trygve; Grimsmo, Jostein; Atar, Dan & Halvorsen, Sigrun [Show all 8 contributors for this article] (2021). Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology. Journal of Healthcare Engineering. ISSN 2040-2295. 2021. doi: 10.1155/2021/5230947. Full text in Research Archive Show summary

  Background. Heart rhythm disorders, especially atrial fibrillation (AF), are increasing global health challenges. Conventional diagnostic tools for assessment of rhythm disorders suffer from limited availability, limited test duration time, and usability challenges. There is also a need for out-of-hospital investigation of arrhythmias. Therefore, the Norwegian ECG247 Smart Heart Sensor has been developed to simplify the assessment of heart rhythm disorders. The current study aimed to evaluate the diagnostic accuracy and usability of the ECG247 Smart Heart Sensor compared to conventional Holter monitors. Methods. Parallel tests with ECG247 Smart Heart Sensor and a Holter monitor were performed in 151 consecutive patients referred for out-of-hospital long-term ECG recording at Sorlandet Hospital Arendal, Norway. All ECG data were automatically analysed by both systems and evaluated by hospital physicians. Participants were asked to complete a questionnaire scoring usability parameters after the test. Results. A total of 150 patients (62% men, age 54 (±17) years) completed the study. The ECG quality from both monitors was considered satisfactory for rhythm analysis in all patients. AF was identified in 9 (6%) patients during the period with parallel tests. The diagnostic accuracy for automatic AF detection was 95% (95% CI 91–98) for the ECG247 Smart Heart Sensor and 81% (95% CI 74–87) for the Holter system. The proportion of false-positive AF was 4% in tests analysed by the ECG247 algorithm and 16% in tests analysed by the Holter algorithm. Other arrhythmias were absent/rare. The system usability score was significantly better for ECG247 Smart Heart Sensor compared to traditional Holter technology (score 87.4 vs. 67.5, ). Conclusions. The ECG247 Smart Heart Sensor showed at least comparable diagnostic accuracy for AF and improved usability compared to conventional Holter technology. ECG247 allows for prolonged monitoring and may improve detection of AF. Trial reg: https://clinicaltrials.gov/ct2/show/NCT04700865.

• Oberprieler, Nikolaus G.; Farahmand, Bahman; Cameron, Jamie; Brobert, Gunnar; Jonasson, Christian & Atar, Dan (2021). Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nationwide population-based cohort study in Norway. Fundamental & Clinical Pharmacology. ISSN 0767-3981. doi: 10.1111/fcp.12744. Full text in Research Archive
• Pope, Marita Knudsen; Hall, Trygve S; Schirripa, Valentina; Radic, Petra; Virdone, Saverio & Pieper, Karen S [Show all 13 contributors for this article] (2021). Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: Observational study using prospectively collected registry data. BMJ (Clinical Research Edition). ISSN 0959-8138. 375. doi: 10.1136/bmj-2021-066450. Full text in Research Archive Show summary

  Objective: To investigate the clinical outcomes of patients who underwent cardioversion compared with those who did not have cardioverson in a large dataset of patients with recent onset non-valvular atrial fibrillation. Design: Observational study using prospectively collected registry data (Global Anticoagulant Registry in the FIELD-AF-GARFIELD-AF). Setting: 1317 participating sites in 35 countries. Participants: 52 057 patients aged 18 years and older with newly diagnosed atrial fibrillation (up to six weeks' duration) and at least one investigator determined stroke risk factor. Main outcome measures: Comparisons were made between patients who received cardioversion and those who had no cardioversion at baseline, and between patients who received direct current cardioversion and those who had pharmacological cardioversion. Overlap propensity weighting with Cox proportional hazards models was used to evaluate the effect of cardioversion on clinical endpoints (all cause mortality, non-haemorrhagic stroke or systemic embolism, and major bleeding), adjusting for baseline risk and patient selection. Results: 44 201 patients were included in the analysis comparing cardioversion and no cardioversion, and of these, 6595 (14.9%) underwent cardioversion at baseline. The propensity score weighted hazard ratio for all cause mortality in the cardioversion group was 0.74 (95% confidence interval 0.63 to 0.86) from baseline to one year follow-up and 0.77 (0.64 to 0.93) from one year to two year follow-up. Of the 6595 patients who had cardioversion at baseline, 299 had a follow-up cardioversion more than 48 days after enrolment. 7175 patients were assessed in the analysis comparing type of cardioversion: 2427 (33.8%) received pharmacological cardioversion and 4748 (66.2%) had direct current cardioversion. During one year follow-up, event rates (per 100 patient years) for all cause mortality in patients who received direct current and pharmacological cardioversion were 1.36 (1.13 to 1.64) and 1.70 (1.35 to 2.14), respectively. Conclusion: In this large dataset of patients with recent onset non-valvular atrial fibrillation, a small proportion were treated with cardioversion. Direct current cardioversion was performed twice as often as pharmacological cardioversion, and there appeared to be no major difference in outcome events for these two cardioversion modalities. For the overall cardioversion group, after adjustments for confounders, a significantly lower risk of mortality was found in patients who received early cardioversion compared with those who did not receive early cardioversion. Study registration: ClinicalTrials.gov NCT01090362.

• Chiang, Cho-Han; Chiang, Cho-Hung; Pickering, John W; Stoyanov, Kiril M.; Chew,, Derek P. & Neumann, Johannes T. [Show all 38 contributors for this article] (2021). Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction. An International Collaborative Meta-analysis. Annals of Internal Medicine. ISSN 0003-4819. doi: 10.7326/M21-1499.
• Täger, Tobias; Frankenstein, Lutz; Atar, Dan; Agewall, Stefan; Frey, Norbert & Grundtvig, Morten [Show all 9 contributors for this article] (2021). Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clinical Research in Cardiology. ISSN 1861-0684. doi: 10.1007/s00392-021-01913-z. Full text in Research Archive Show summary

  Background: Receptor selectivity of sodium-glucose cotransporter-2 inhibitors (SGLT2i) varies greatly between agents. The overall improvement of cardiovascular (CV) outcomes in heart failure (HF) patients varies between trials. We, therefore, evaluated the comparative efficacy of individual SGLT2i and the influence of their respective receptor selectivity thereon. Methods: We identified randomized controlled trials investigating the use of SGLT2i in patients with HF-either as the target cohort or as a subgroup of it. Comparators included placebo or any other active treatment. The primary endpoint was the composite of hospitalization for HF or CV death. Secondary outcomes included all-cause mortality, CV mortality, hospitalization for HF, worsening renal function (RF), and the composite of worsening RF or CV death. Evidence was synthesized using network meta-analysis. In addition, the impact of receptor selectivity on outcomes was analysed using meta-regression. Results: We identified 18,265 patients included in 22 trials. Compared to placebo, selective and non-selective SGLT2i improved fatal and non-fatal HF events. Head-to-head comparisons suggest superior efficacy with sotagliflozin as compared to dapagliflozin, empagliflozin or ertugliflozin. No significant difference was found between canagliflozin and sotagliflozin. Meta-regression analyses show a decreasing benefit on HF events with increasing receptor selectivity of SGLT2i. In contrast, receptor selectivity did not affect mortality and renal endpoints and no significant difference between individual SGLT2i was noted. Conclusion: Our data point towards a class-effect of SGLT2i on mortality and renal outcomes. However, non-selective SGLT2i such as sotagliflozin may be superior to highly selective SGLT2i in terms of HF outcomes. Keywords: Diabetes mellitus; Heart failure; Outcome; Receptor selectivity; Sodium glucose cotransporter 2 inhibitor. © 2021. The Author(s).

• Pope, Marita K; Atar, Dan; Svilaas, Arne B; Hole, Torstein; Nielsen, Jørn Dalsgaard & Hintze, Ulrik [Show all 17 contributors for this article] (2021). Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation–results from the GARFIELD-AF registry. Annals of Medicine. ISSN 0785-3890. 53(1), p. 485–494. doi: 10.1080/07853890.2021.1893897. Full text in Research Archive Show summary

  Aims: The objective was to evaluate the clinical characteristics, management and two-year outcomes of patients with newly diagnosed non-valvular atrial fibrillation at risk for stroke in Nordic countries. Methods: We examined the baseline characteristics, antithrombotic treatment, and two-year clinical outcomes of patients from four Nordic countries. Results: A total of 52,080 patients were enrolled in the GARFIELD-AF. Out of 29,908 European patients, 2,396 were recruited from Nordic countries. The use of oral anticoagulants, alone or in combination with antiplatelet (AP), was higher in Nordic patients in all CHA2DS2-VASc categories: 0-1 (72.8% vs 60.3%), 2-3 (78.7% vs 72.9%) and ≥4 (79.2% vs 74.1%). In Nordic patients, NOAC ± AP was more frequently prescribed (32.0% vs 27.7%) and AP monotherapy was less often prescribed (10.4% vs 18.2%) when compared with Non-Nordic European patients. The rates (per 100 patient years) of all-cause mortality and non-haemorrhagic stroke/systemic embolism (SE) were similar in Nordic and Non-Nordic European patients [3.63 (3.11-4.23) vs 4.08 (3.91-4.26), p value = .147] and [0.98 (0.73-1.32) vs 1.02 (0.93-1.11), p value = .819], while major bleeding was significantly higher [1.66 (1.32-2.09) vs 1.01 (0.93-1.10), p value < .001]. Conclusion: Nordic patients had significantly higher major bleeding than Non-Nordic-European patients. In contrast, rates of all-cause mortality and non-haemorrhagic stroke/SE were comparable. Clinical trial registration: Unique identifier: NCT01090362. URL: http://www.clinicaltrials.gov. Key message: Nordic countries had significantly higher major bleeding than Non-Nordic-European countries. Rates of mortality and non-haemorrhagic stroke/SE were similar . Keywords: Atrial fibrillation; Nordic countries; antithrombotic treatment; stroke prevention. 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

• Atar, Dan; Jukema, J. Wouter; Molemans, Bart; Taub, Pam R.; Goto, Shinya & Mach, François [Show all 11 contributors for this article] (2021). New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. ISSN 0021-9150. 319, p. 51–61. doi: 10.1016/j.atherosclerosis.2020.12.013. Full text in Research Archive
• Maqsood, Muhammad H.; Alam, Mahboob; Atar, Dan & Birnbaum, Yochai (2021). Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology. ISSN 0160-2446. 77(1), p. 87–93. doi: 10.1097/FJC.0000000000000922. Full text in Research Archive
• Camm, A. John & Atar, Dan (2021). Use of non-vitamin K antagonist oral anticoagulants for stroke prevention across the stroke spectrum: Progress and prospects. Thrombosis and Haemostasis. ISSN 0340-6245. p. 1–15. doi: 10.1055/s-0040-1721665.
• Johannessen, Tonje R.; Atar, Dan; Vallersnes, Odd Martin; Larstorp, Anne Cecilie Kjeldsen; Mdala, Ibrahimu & Halvorsen, Sigrun (2021). Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study. BMJ Open. ISSN 2044-6055. 11(2). doi: 10.1136/bmjopen-2020-046024. Full text in Research Archive
• De Caterina, Raffaele; Patti, Giuseppe; Westerbergh, Johan; Horowitz, John; Ezekowitz, Justin A & Lewis, Basil S [Show all 16 contributors for this article] (2020). Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 8(3), p. 227–235. doi: 10.1093/ehjcvp/pvaa140.
• Bassand, Jean-Pierre; Apenteng, Patricia N; Atar, Dan; Camm, A. John; Cools, Frank & Corbalan, Ramon [Show all 22 contributors for this article] (2020). GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiology. ISSN 1479-6678. doi: 10.2217/fca-2020-0014.
• Birnbaum, Yochai; Levine, Glenn; French, John; Kaski, Juan Carlos; Atar, Dan & Alam, Mahboob [Show all 9 contributors for this article] (2020). Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines? Cardiovascular Drugs and Therapy. ISSN 0920-3206. 34(6), p. 865–870. doi: 10.1007/s10557-020-07039-0. Full text in Research Archive
• Butt, Noreen; Bache-Mathiesen, Lena Kristin; Ushakova, Anastasia; Nordrehaug, Jan Erik; Jensen, Senn-Erik & Munk, Peter Scott [Show all 15 contributors for this article] (2020). Pentraxin 3 in primary percutaneous coronary intervention for ST elevation myocardial infarction is associated with early irreversible myocardial damage: Kinetic profile, relationship to interleukin 6 and infarct size. European Heart Journal: Acute Cardiovascular Care. ISSN 2048-8726. 9(4), p. 302–312. doi: 10.1177/2048872620923641. Full text in Research Archive
• Bogsrud, Martin Prøven; Øyri, Linn Kristin Lie; Halvorsen, Sigrun; Atar, Dan; Leren, Trond Paul & Holven, Kirsten Bjørklund (2020). Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction. Journal of Clinical Lipidology. ISSN 1933-2874. 14(3), p. 339–345. doi: 10.1016/j.jacl.2020.04.002. Full text in Research Archive
• Stensjøen, Anne Line; Hommerstad, Anders; Halvorsen, Sigrun; Arheden, Håkan; Engblom, Henrik & Erlinge, David [Show all 11 contributors for this article] (2020). Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Annals of Noninvasive Electrocardiology. ISSN 1082-720X. 25(6). doi: 10.1111/anec.12784. Full text in Research Archive
• Zamorano, Jose-Luis; Gottfridsson, Christer; Asteggiano, Riccardo; Atar, Dan; Badimon, Lina & Bax, Jeroen J. [Show all 19 contributors for this article] (2020). The cancer patient and cardiology. European Journal of Heart Failure. ISSN 1388-9842. p. 1–20. doi: 10.1002/ejhf.1985. Full text in Research Archive
• Atar, Dan; Berge, Eivind; Le Heuzey, Jean-Yves; Virdone, Saverio; Camm, A. John & Steffel, Jan [Show all 15 contributors for this article] (2020). The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. Europace. ISSN 1099-5129. 22(2), p. 195–204. doi: 10.1093/europace/euz292. Full text in Research Archive
• Lambert, Anna Tancin; Kong, Xiang Yi; Ratajczak-Tretel, Barbara; Atar, Dan; Russell, David & Skjelland, Mona Elisabet [Show all 13 contributors for this article] (2020). Biomarkers Associated with Atrial Fibrillation in Patients with Ischemic Stroke: A Pilot Study from the NOR-FIB Study. Cerebrovascular Diseases Extra. ISSN 1664-5456. 10(1), p. 11–20. doi: 10.1159/000504529. Full text in Research Archive
• Johannessen, Tonje R.; Vallersnes, Odd Martin; Halvorsen, Sigrun; Larstorp, Anne Cecilie Kjeldsen; Mdala, Ibrahimu & Atar, Dan (2020). Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study. Open heart. ISSN 2053-3624. 7:e001296, p. 1–9. doi: 10.1136/openhrt-2020-001296. Full text in Research Archive
• Aamodt, Anne Hege; Bjørk, Marte-Helene; Tronvik, Erling Andreas; Buanes, Eirik Alnes; Stovner, Lars Jacob & Atar, Dan (2020). Gir ACE-hemmere og angiotensinreseptorantagonister økt risiko for alvorlig covid-19? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 140(9). doi: 10.4045/tidsskr.20.0411.
• Aamodt, Ina Thon; Lycholip, Edita; Celutkiené, Jelena; von Lueder, Thomas Gero; Atar, Dan & Falk, Ragnhild Sørum [Show all 10 contributors for this article] (2020). Self-Care Monitoring of Heart Failure Symptoms and Lung Impedance at Home Following Hospital Discharge: Longitudinal study. Journal of Medical Internet Research. ISSN 1438-8871. 22. doi: 10.2196/15445. Full text in Research Archive
• Täger, Tobias; Atar, Dan; Agewall, Stefan; Katus, Hugo A.; Grundtvig, Morten & Cleland, John G.F. [Show all 9 contributors for this article] (2020). Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews. ISSN 1382-4147. p. 1–15. doi: 10.1007/s10741-020-09954-8. Full text in Research Archive Show summary

  Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2D). The comparative efficacy of individual SGLT2i remains unclear. We searched PubMed, www.clinicaltrials.gov and the Cochrane Central Register of Controlled Trials for randomised controlled trials exploring the use of canagliflozin, dapagliflozin, empagliflozin or ertugliflozin in patients with T2D. Comparators included placebo or any other active treatment. The primary endpoint was all-cause mortality. Secondary endpoints were cardiovascular mortality and worsening heart failure (HF). Evidence was synthesised using network meta-analysis (NMA). Sixty-four trials reporting on 74,874 patients were included. The overall quality of evidence was high. When compared with placebo, empagliflozin and canagliflozin improved all three endpoints, whereas dapagliflozin improved worsening HF. When compared with other SGLT2i, empagliflozin was superior for all-cause and cardiovascular mortality reduction. Empagliflozin, canagliflozin and dapagliflozin had similar effects on improving worsening HF. Ertugliflozin had no effect on any of the three endpoints investigated. Sensitivity analyses including extension periods of trials or excluding studies with a treatment duration of < 52 weeks confirmed the main results. Similar results were obtained when restricting mortality analyses to patients included in cardiovascular outcome trials (n = 38,719). Empagliflozin and canagliflozin improved survival with empagliflozin being superior to the other SGLT2i. Empagliflozin, canagliflozin and dapagliflozin had similar effects on improving worsening HF. Prospective head-to-head comparisons would be needed to confirm these results. Keywords Sodium-glucose cotransporter-2 inhibitors . Type 2 diabetes . Mortality . Heart failure . Efficacy

• Savarese, Gianluigi; Reiner, Martin F; Uijl, Alicia; D'Amario, Domenico; Agewall, Stefan & Atar, Dan [Show all 23 contributors for this article] (2020). Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 6(2), p. 86–93. doi: 10.1093/ehjcvp/pvz036. Full text in Research Archive

View all works in Cristin

• Jervan, Øyvind; Haukeland-Parker, Stacey Marie; Gleditsch, Jostein; Tavoly, Mazdak; Klok, Frederikus A. & Steine, Kjetil [Show all 14 contributors for this article] (2023). Rehabilitation to improve exercise capacity and quality of life after pulmonary embolism.
• Andel, Peter Michael; Aukrust, Pål; Gleditsch, Jostein; Gude, Einar; Haugeberg, Glenn & Høie, Sverre [Show all 9 contributors for this article] (2023). Recurrent pericarditis. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(8), p. 708–711. doi: 10.4045/tidsskr.22.0580. Full text in Research Archive
• Bakken, Arnhild; Atar, Dan; Ruddox, Vidar; Halvorsen, Sigrun & Munkhaugen, John (2023). BETABLOKKERE ETTER HJERTEINFARKT– SKAL DEN FORTSATT GIS? Hjerteposten : fagtidsskrift for NSFs landsgruppe av kardiologiske sykepleiere. ISSN 1891-2532. p. 28–32. Show summary

  Betablokkere har vært standard sekundærforebyggende behandling etter akutt hjerteinfarkt siden 1980-tallet. Siden den gang har diagnostikken og behandlingen av hjerteinfarkt forandret seg betydelig. Om betablokkere fortsatt er nyttig, skal BETAMI-studien gi svar på. Studien startet opp i oktober 2018 og er en av de største ikke-industrisponsede hjertestudiene som er gjennomført i Norge.

• semb, anne grete; Vesterbekk, Elisabeth Kleivhaug; Retterstøl, Kjetil; Atar, Dan; Solberg, Erik E. & Schirmer, Henrik [Show all 11 contributors for this article] (2023). PCSK9-hemmere på blå resept for hvem? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(8). doi: 10.4045/tidsskr.23.0191.
• Atar, Dan; Bakken, Arnhild & Munkhaugen, John (2023). Achieving the unachievable: How to optimize lipid-lowering therapy in survivors of acute myocardial infarction. Kardiologia polska. ISSN 0022-9032. 81(4), p. 327–329. doi: 10.33963/KP.a2023.0087.
• Aunan, Kristin; Atar, Dan & Agewall, Stefan (2023). Klima - en hjertesak. Hjerteforum. ISSN 0802-1465. 1, p. 54–61.
• Taegtmeyer, Heinrich & Atar, Dan (2021). Icons in Cardiology. Cardiology. ISSN 0008-6312. 146(6). doi: 10.1159/000519019.
• Marciniak, Thomas A; Atar, Dan & Serebruany, Victor (2021). The perils of data sharing, meta-analyses, and estimating cardiovascular risk. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 7(3), p. E55–E57. doi: 10.1093/ehjcvp/pvaa109.
• Rubboli, Andrea & Atar, Dan (2021). The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confused. European journal of internal medicine. ISSN 0953-6205. 90, p. 125–126. doi: 10.1016/j.ejim.2021.05.009.
• Bondjers, Kristina; Stensland, Synne; Zwart, John Anker Henrik; Rosseland, Leiv Arne; Wøien, Hilde & Atar, Dan [Show all 11 contributors for this article] (2021). Hvordan gikk det? Støtte og stolthet gjennom pandemien - rapport fra en longitudinell studie av 2000 sykehuspersonell.
• Bondjers, Kristina; Stensland, Synne; Zwart, John Anker Henrik; Rosseland, Leiv Arne; Wøien, Hilde & Atar, Dan [Show all 11 contributors for this article] (2021). Hvordan gikk det? Støtte og stolthet gjennom pandemien - rapport fra en longitudinell studie av 2000 sykehuspersonell.
• Bondjers, Kristina; Stensland, Synne; Zwart, John Anker Henrik; Rosseland, Leiv Arne; Wøien, Hilde & Atar, Dan [Show all 11 contributors for this article] (2021). Psychological impact of the Covid-19 pandemic on healthcare workers.
• Johannessen, Tonje Rambøll; Halvorsen, Sigrun; Atar, Dan; Munkhaugen, John; Nore, Anne Kathrine & Wisløff, Torbjørn [Show all 7 contributors for this article] (2021). Cost-minimization analysis of acute myocardial infarction rule-out in low-risk patients: emergency primary care versus hospital.
• Stensland, Synne; Bondjers, Kristina; Zwart, John Anker Henrik; Rosseland, Leiv Arne; Wøien, Hilde & Atar, Dan [Show all 11 contributors for this article] (2021). Did hospital personnel receive adequate help and support to reduce work-related stress during the Covid-19 pandemic? The Norwegian Study of Hospital Personnel.
• Johannessen, Tonje Rambøll; Halvorsen, Sigrun; Atar, Dan; Munkhaugen, John; Nore, Anne Kathrine & Wisløff, Torbjørn [Show all 7 contributors for this article] (2021). Cost-minimisation analysis of acute myocardial infarction rule-out in low-risk patients: primary care emergency setting versus hospital setting.
• Bondjers, Kristina; Lingaas, Ingebjørg; Stensland, Synne; Wøien, Hilde; Muller, Ashley Elizabeth & Atar, Dan [Show all 8 contributors for this article] (2021). Is it all bad? - sense of accomplishment among health-care workers during the Covid-19 pandemic.
• Kristensen, Anna Meta Dyrvig; Bovin, Ann; Zwisler, Ann-Dorthe O.; Cerquira, Charlotte; Torp-Pedersen, Christian & Bøtker, Hans Erik [Show all 21 contributors for this article] (2020). Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: Study protocol for a randomized controlled trial. Trials. ISSN 1745-6215. 21(1). doi: 10.1186/s13063-020-4214-6.
• Johannessen, Tonje R.; Atar, Dan; Vallersnes, Odd Martin; Larstorp, Anne Cecilie Kjeldsen; Mdala, Ibrahimu & Halvorsen, Sigrun (2020). A single high-sensitivity cardiac troponin T compared to the HEART score for a rapid rule-out of acute myocardial infarction at a prehospital emergency clinic . European Heart Journal. ISSN 0195-668X. 41. doi: 10.1093/ehjci/ehaa946.1680.
• Khatami, Mohsen; Pope, Marita Knudsen; Le Page, Sophie; Radic, Petra; Schirripa, Valentina & Grundvold, Irene [Show all 7 contributors for this article] (2020). Cardioversion safety - Are we doing enough? Cardiology. ISSN 0008-6312. 145(11), p. 740–745. doi: 10.1159/000509343. Full text in Research Archive Show summary

  There is a considerable periprocedural risk of thromboembolic events in atrial fibrillation patients undergoing cardioversion, and treatment with anticoagulants is therefore a hallmark of cardioversion safety. Based on retrospective subgroup analyses and prospective studies, non-vitamin K anticoagulants are at least as efficient as vitamin K-antagonists in preventing thromboembolic complications after cardioversion. The risk of thromboembolic complications after cardioversion very much depends on the comorbidities in a given patient, and especially heart failure, diabetes, and age >75 years carry a markedly increased risk. Cardioversion has been considered safe within a 48-h time window after onset of atrial fibrillation without prior treatment with anticoagulants, but recent studies have set this practice into question based on e.g. erratic debut assessment of atrial fibrillation. Therefore, a simple and more practical approach is here suggested, where early cardioversion is performed only in hemodynamically unstable patients. Keywords: Anticoagulation; Atrial fibrillation; Cardioversion; Safety; Stroke prevention. © 2020 The Author(s) Published by S. Karger AG, Basel.

• Atar, Dan (2020). Meet the Experts Focused Case Discussions .
• Thind, M.; Zareba, W.; Atar, Dan; Crijns, H; Zhu, J & Pak, H-N [Show all 11 contributors for this article] (2020). Efficacy and safety of dronedarone vs placebo in patients with atrial fibrillation or atrial flutter across a spectrum of renal function: post hoc analyses of the EURIDIS-ADONIS trials .
• Pope, Marita Knudsen; Ghanima, Waleed & Atar, Dan (2020). Intensivering av antitrombotisk behandling ved kronisk aterosklerotisk sykdom. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 140(10). doi: 10.4045/tidsskr.20.0066.
• Johannessen, Tonje R.; Atar, Dan; Vallersnes, Odd Martin; Larstorp, Anne Cecilie Kjeldsen; Mdala, Ibrahimu & Halvorsen, Sigrun (2020). A single high-sensitivity cardiac troponin T compared to the HEART score for a rapid rule-out of acute myocardial infarction at a prehospital emergency clinic .
• Hall, Trygve Sørdahl; Orn, S; Zanned, F.; Rossignol, Patrick; Duarte, K. & Solomon, S. [Show all 10 contributors for this article] (2020). The association of smoking to cardiovascular death differs according to age and sex following myocardial infarction complicated by heart failure or left ventricular dysfunction .
• Johannessen, Tonje R.; Vallersnes, Odd Martin; Larstorp, Anne Cecilie Kjeldsen; Mdala, Ibrahimu; Atar, Dan & Halvorsen, Sigrun (2020). Fast prehospital rule-out using a high-sensitivity cardiac Troponin T assay in a low-prevalence population for Acute Coronary Syndrome (The OUT-ACS study).
• Marti, Hans Peter; Serebruany, Victor L. & Atar, Dan (2019). Challenging Anticoagulation in Advanced Renal Failure. American Journal of Medicine. ISSN 0002-9343. 132(11), p. 1258–1259. doi: 10.1016/j.amjmed.2019.07.002.
• Kjeldsen, Sverre; Atar, Dan & von Lueder, Thomas Gero (2019). Angiotensin receptor neprilysin inhibition for the treatment of hypertension: The neglected child in cardiovascular pharmacotherapy. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 5(2), p. 122–123. doi: 10.1093/ehjcvp/pvz005.

View all works in Cristin